Team:HKUST-Hong Kong/Module/Anti tumor

From 2012.igem.org

(Difference between revisions)
Line 289: Line 289:
           <div class="Navigation_Content" id="Project_Content">
           <div class="Navigation_Content" id="Project_Content">
               <div class="Content_Buttons"><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Project_Abstraction">Project Abstract</a></p></div>
               <div class="Content_Buttons"><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Project_Abstraction">Project Abstract</a></p></div>
-
              <div class="Content_Buttons"><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Background_and_Motive">Background and<br> Motive</a></p></div>
 
               <div class="Content_Buttons"><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Project">Project Description</a></p></div>
               <div class="Content_Buttons"><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Project">Project Description</a></p></div>
 +
              <div class="Content_Buttons"><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Background_and_Motive">Background and<br> Motive</a></p></div>
               <div class="Content_Buttons"><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Module">Module</a></p></div>
               <div class="Content_Buttons"><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Module">Module</a></p></div>
               <div class="Content_Buttons"><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Chassis">Chassis</a></p></div>
               <div class="Content_Buttons"><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Chassis">Chassis</a></p></div>

Revision as of 14:49, 25 September 2012

Team:HKUST-Hong Kong - 2012.igem.org

DRUG SYNTHESIZING MODULE

<<< Back to Module

As our team objective is to provide a specific and efficient drug for Colon cancer, the way of drug synthesis and release is a significant part of our whole project. Hence this module is focusing on the production and delivery of anti-tumor drug. Synthesis of the drug is achieved by engineering bacteriawhich is able to produce and secrete anti-tumor molecule. Release of anti-tumor molecule to extracellular system is attained by secretion of recombinant gene product under the facilitation of signaling peptide.


Among hundreds of studied anti-tumor chemokine, BMP-2, Bone morphogenetic protein 2 has caught our attention as the “drug” of our project. BMP-2 is a signaling molecule in BMP pathway, which belongs to the TGF-β superfamily. One function of BMP pathway is to induce cell differentiation, especially in the development of bone and cartilage. BMP stimulates the formation of bone by inducing the cell differentiation of bone cells. On the other hand, BMP-2 has also been suggested to have high apoptotic activity towards colon cancer cells (Beck et al., 2005). According to Beck et al., Colon cancers which are treated with 100 ng/mL BMP-2 for 48 hours show significant decrease in cell growth. Hence, it is a potential drug to fight colon cancer. Therefore, we incorporate mature BMP-2 gene in our construct and transform it into our chosen bacterial vector.


Furthermore, choice of chassis also has important role to ensure the secretion BMP-2. B. subtilis, which is a probiotic, is chosen as the chassis because of its harmless activity towards human, and high secretory activity which is important for delivery of BMP-2 to the environment. To mimic the secretory activity of B.subtilis, we add signaling peptide type I gene, which works mostly through secretory pathway, at the upstream of BMP-2 in our construct (Tjalsma et al, 2000). That way, signaling peptide is translated together with BMP-2 as a whole peptide, and delivered to the cell membrane. Once it reaches cell membrane, BMP-2 is separated from signaling peptide by signal peptidase (Spase). BMP-2 is then transferred outside the cell and fold into its native conformation, while signal peptide is degraded by signal peptide peptidase (SPPases) (Tjalsma et al, 2000).


However, among hundreds of signaling peptide, we need to choose signaling peptide that allows the secretion of correct mature BMP-2 in appropriate amount. Therefore we choose YbdN, which is the highest efficiency signaling peptide and YdjM, the signaling peptide whichsupport accurate cleavage from Spase. . We had not been able to choose between the two choices until we construct two constructs consisting of YdjM or YbdN gene at the upstream of BMP-2 gene and characterize both signaling peptide.


Although research has shown E.coli can produce BMP-2 (Yuvaraj et al, 2012). No one has made a recombinant protein BMP-2 in B. subtilis. We need to test the function of BMP-2 produced from B. subtilis. This is also the achievement of our group.


 

References
Beck, S. E., Jung, B. H., Fiorino, A., Gomez, J., Del Rosario, E., Cabrera, B. L., Huang, S. C., Chow, J. Y. C., & Carethers J.M. (2006). Bone morphogenetic protein signaling and growth suppression in colon cancer. The American Journal of Physiology-Gastrointestinal and Liver Physiology291(1), G135-G145.

Ernesto, C. (2000). “Skeletal Growth Factors”. LIPPINCOTT WILLIAMS&WILKINS.

Hardwick,J.C., Van Den Brink,G.R., Bleuming,S.A., Ballester,I., Van Den
Brande,J.M., Keller,J.J., Offerhaus,G.J., Van Deventer,S.J., Peppelenbosch,M.P., 2004.
Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in
the colon. Gastroenterology 2004. Jan. ;126. (1):111. -21. 126, 111-121.

Saravanan Yuvaraj, Sa’ad H. Al-Lahham, Rajesh Somasundaram, Patrick A. Figaroa, Maikel P. Peppelenbosch, and Nicolaas A. Bos, E. coli-Produced BMP-2 as a Chemopreventive Strategy for Colon Cancer: A Proof-of-Concept Study. Gastroenterology Research and Practice, vol. 2012, Article ID 895462, 6 pages, 2012. doi:10.1155/2012/895462

Tjalsma, H., Bolhuis, A., Jongbloed, J. D. H., Bron, S., & Dijl, J. M. V. (2000). Signal peptide-dependent protein transport in bacillus subtilis: a genome-based survey of the secretome. Microbiology and Molecular Biology Reviews64(3), 515-547.

Last Module

Next Module